Please ensure Javascript is enabled for purposes of website accessibility

Microsoft Is All In With Growing Its Scientific Research Arm

By Donna Fuscaldo - Mar 16, 2020 at 9:09AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Microsoft is overhauling its research unit, bringing the healthcare business into the fold as it aims to lead in a host of fast-growing markets.

Microsoft (MSFT -0.96%) is overhauling its scientific research unit, naming a veteran employee as its first-ever chief scientific officer.

It's an uncommon move for a technology company, but it does underscore the importance of research to Microsoft's operations. As the company strives to lead in artificial intelligence, augmented reality, and healthcare technology, scientific research is necessary. 

When announcing the appointment of Eric Horvitz (the director of Microsoft's Research Labs) as its chief scientific officer, Microsoft said Horvitz will play a key role in guiding the company's "scientific directions and capabilities." That means Horvitz will be tasked with choosing the areas to focus on, and the investments to be made.

In a blog post, Horvitz said the unit will concentrate its efforts in biology, medical informatics, physics, sustainability, economics, and the social and behavioral sciences.

"The focus of the chief scientist position is to provide cross-company leadership on advances and trends related to scientific matters and on important issues and opportunities arising at the intersection of science, technology, and society," wrote Horvitz.

Two researchers in a lab.

Image source: Getty Images.

Microsoft focuses on the healthcare market with its reorg 

As part of the reorganization, Microsoft is putting the entire unit under the leadership of a single executive who has also played a role in its healthcare business. The aim is to enable Microsoft's healthcare product teams and scientists to work better together. Microsoft has been moving to unify its healthcare businesses under one unit, as it pushes further into that market. 

For Microsoft, there are several revenue opportunities a deep research arm can bring. There's the product development side, for starters. Microsoft is creating healthcare provider tools, churning out products, and inking partnerships with big names in the healthcare industry.

In the fall it announced an alliance with Novartis to speed the development of new drugs. It's an area in much need of fixing. As it stands, it costs $2.6 billion on average for a pharmaceutical company to introduce a new drug.

Earlier in March, Microsoft added a new feature to its Teams collaboration and chat platform to make it easier for healthcare providers to deliver virtual care. Through the new Bookings feature, healthcare professionals can book virtual appointments.

Since the novel coronavirus outbreak, Microsoft has seen increased demand for its Teams platform. In China alone, Microsoft saw a 500% spike in usage during the quarantines. In the U.S., with schools and offices closing and events getting canceled, Microsoft expects a bigger uptick.

The new Teams feature should also see more usage as healthcare providers contend with an influx of sick patients. On top of that, Microsoft is also developing healthcare bots and creating APIs for sharing health records.

The cloud is big business for Microsoft 

Then, there is the cloud side. Microsoft's cloud computing business is extremely important to its future growth and a big revenue driver today.

In its fiscal second quarter, Azure revenue was up 62%. Nevertheless, it is a distant second-place player to Amazon's Amazon Web Services. Microsoft wants to change that, and it views healthcare as one of the ways to do so.

The healthcare market is inundated with data and new regulations around how to handle that data. Healthcare companies are overwhelmed and overworked, and as a result, are increasingly turning to cloud providers for help. According to IDC, healthcare companies were expected to spend $12 billion on the cloud last year. That figure is projected to rise in 2020 and beyond. That's a big opportunity for Microsoft.

In order to succeed, Microsoft will need to innovate, and that's where the R&D focus comes in. Microsoft is not only providing healthcare companies with a safe place to store their data, but it has to come up with new services to help them harness that information.

In addition to pouring money into its own R&D, Microsoft has been actively investing money into digital health startups. According to CB Insights, Microsoft, along with Alphabet's Google and Tencent accounted for 70% of the investments made in digital health startups from big tech companies during 2019.

Research and development is an integral part of a thriving tech company that wants to be around in the years to come. Microsoft recognizes that and is making moves to better align those efforts. In increasingly uncertain times, it may turn out to be a winning strategy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Microsoft Corporation Stock Quote
Microsoft Corporation
$265.14 (-0.96%) $-2.56

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/27/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.